Late last week, United States Patent and Trademark Office (USPTO) Director Kathi Vidal announced in a blog post that the agency had issued a notice in the Federal Register, which was published on Friday, to clarify the duties of disclosure and reasonable inquiry for pharmaceutical patent applicants, as well as parties to Patent Trial and Appeal Board (PTAB) proceedings. The notice was specifically targeted to parties proceeding before both the USPTO and Food and Drug Administration (FDA) and was issued in response to urging by Senators to establish interagency communications aimed in part at eliminating so-called drug patent thickets.
Vidal Takes Next Step on Senators’ Call to Curb Inconsistencies in USPTO/FDA Statements
- 1 min read
Cuba’s new parliament will face a familiar economic hangover
Slammed by sanctions, the pandemic, and high inflation, Havana is making piecemeal reforms which may not be enough.
Kamala Harris to discuss China influence, debt distress in Africa
The US has unleashed a charm offensive in Africa under President Biden as it seeks to rival Russia and China.
‘We shouldn’t have been there’: US vets consider legacy of Iraq
Twenty years after the US invasion of Iraq, veterans question its purpose and struggle with the lingering effects.